Zydus Wellness Limited (ZYDUSWELL) — Financial Results | 4 August 2026(4 announcements)

· NSE 🔴 High Importance Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
1 Financial Results 🔴 High Importance Neutral 📄 PDF

Investor Takeaways

  • Revenue of ₹461.9 Cr reported for Q3FY25, up from ₹492.9 Cr in Q2FY25
  • Net profit declined to ₹6.4 Cr in Q3FY25 from ₹20.9 Cr in Q2FY25
  • ⚠️ Net profit margin fell significantly to 1.39% in Q3FY25 from 4.24% in Q2FY25
  • Overall Tone: Cautious based on the numbers only.

    Key Financial Highlights

    MetricValueYoY Change
    Revenue₹461.9 CrN/A
    Net Profit₹6.4 CrN/A
    EBITDAN/AN/A
    EPS[amount context mismatch]N/A
    OPM3.2%N/A

    What Changed

    The filing reveals a sharp decline in quarterly performance metrics. Revenue fell to ₹461.9 Cr in Q3FY25 from ₹492.9 Cr in the previous quarter (Q2FY25), representing a sequential drop of approximately 6.3%. More significantly, net profit plummeted to ₹6.4 Cr from ₹20.9 Cr in Q2FY25, indicating a 69.4% sequential decline. Operating profit margin also contracted sharply to 3.2% from 3.98% in Q2FY25. Earnings per share decreased to ₹1.01 from ₹3.28 in the prior quarter. These trends suggest weakening profitability despite revenue levels in the most recent quarter. The filing only provides audio recording availability and does not include detailed financial statements or forward-looking commentary.

    Peer Comparison

    CompanyP/EROEROCEMarket Cap (₹ Cr)
    Zydus Wellness Limited49.13N/AN/A15,976.44
    Hindustan Unilever Limited36.7929.38%27.39%5,33,874.13
    ITC Limited11.0650.02%38.91%3,87,724.39
    Nestle India Limited84.5981.33%93.64%2,75,845.36

    Zydus Wellness Limited trades at a premium valuation compared to ITC and Nestle India, but below Nestle’s P/E. Peer companies demonstrate higher profitability metrics, with Nestle India showing ROCE of 93.64% and ITC achieving 50.02% ROE. Zydus Wellness has no disclosed ROE or ROCE figures in the provided data.

    Risks & Concerns

  • Declining net profit margins and profitability trends observed in sequential quarterly performance
  • Significant drop in net profit from ₹20.9 Cr in Q2FY25 to ₹6.4 Cr in Q3FY25
  • No specific risks identified in this filing beyond the reported financial trend
  • Quarterly Trend

    QuarterRevenue (₹ Cr)Net Profit (₹ Cr)OPM%
    Q3FY25461.96.43.2%
    Q2FY25492.920.93.98%
    Q1FY25841147.718.47%
    Q4FY24782.6150.320.73%
    2 Financial Results 🔴 High Importance Neutral 📄 PDF
    MetricValue
    Revenue₹14,299 Cr
    Net Profit (PAT)₹1,189 Cr
    📢 Key Event
    Zydus Wellness reports 66.7% YoY net sales growth to ₹14,299 million in Q1 FY27
    🔄 What Changed
    Net sales up 66.7% YoY to ₹14,299 million; EBITDA up 55.3% to ₹2,417 million; net profit at ₹1,189 million
    💡 Investor Takeaway
    Strong top-line growth driven by core brands and new product launches, but nutritional drinks declined.

    Zydus Wellness reported consolidated net sales of ₹14,299 million for Q1 FY27, up 66.7% YoY from ₹8,577 million, with EBITDA rising 55.3% to ₹2,417 million and net profit at ₹1,189 million. Sugar Free held 96.1% market share in its category, while Glucon-D led with 59.1% share. Brands like RiteBite Max Protein and Everyuth expanded leadership positions. The company launched Complanation Power Play and VieMax Diabetes Care, and entered US and UAE e-commerce markets. Nutritional drink category declined, but Complanation maintained fourth rank.

    3 Financial Results 🔴 High Importance Neutral 📄 PDF
    📢 Key Event
    Zydus Wellness Q1 FY27 revenue up 66.7% YoY to ₹14,299 crores
    🔄 What Changed
    Revenue growth accelerated to 66.7% YoY; PAT declined 7% to ₹1,189 crores; EBITDA rose 55.3% to ₹2,417 crores; gross margin improved to 65.5%
    🔮 What's Next
    No explicit future financial guidance or deadlines stated in the document
    💡 Investor Takeaway
    Revenue growth is strong but profitability is under pressure from acquisition costs and amortization.

    Zydus Wellness reported Q1 FY27 revenue of ₹14,299 crores, up 66.7% YoY, driven by strong domestic growth and international expansion. Gross margin improved to 65.5%, while PAT declined 7% to ₹1,189 crores due to higher amortization and finance costs. EBITDA rose 55.3% to ₹2,417 crores with margin at 16.8%. The company highlighted double-digit growth in Sugar Free and Complanation brands, successful launches like Glucon-D Activon, and robust performance in protein snacks and international markets. Key risks include seasonal weakness in North/East India and input cost volatility.

    4 Financial Results 🔴 High Importance Neutral 📄 PDF
    📢 Key Event
    All resolutions passed at the 32nd AGM with majority votes
    💡 Investor Takeaway
    Shareholders approved all key governance and financial proposals, including dividend declaration and director appointments.

    Zydus Wellness Limited announced the results of its Thirty Second Annual General Meeting held on August 4, 2026, confirming the passage of all six resolutions with overwhelming shareholder approval. The meeting was conducted via video conference with remote e-voting and e-voting at the venue, and the Scrutinizer's report validated the voting outcomes. Key approvals included adoption of standalone and consolidated financial statements for FY2026, declaration of a dividend of ₹1.20 per share, re-appointment of Dr. Sharvil P. Patel as Non-Executive Director, appointment of Mr. Apurva S. Diwanji as Independent Director, and ratification of cost auditors' remuneration. Shareholder participation included 61 attendees via video conference and representations for 22.15 million shares, accounting for 69.6% of paid-up capital. The filing also detailed procedural compliance with SEBI and MCA regulations for general meetings.

    About Zydus Wellness Limited (ZYDUSWELL)

    Fast Moving Consumer Goods · FMCG · Listed on NSE

    Market Cap: ₹16,798.89 Cr P/E: 89.2 ROE: 3.2% ROCE: 4.1% Div Yield: 0.23%

    View full ZYDUSWELL stock details →

    📡 Get AI alerts when ZYDUSWELL files next

    Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

    Track ZYDUSWELL — Free

    📊 More ZYDUSWELL filings

    See all ZYDUSWELL filings →

    Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

    Editorial & Data Transparency Notice

    This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

    📡 Get AI alerts when ZYDUSWELL files new disclosures

    Track ZYDUSWELL filings, board meetings, and corporate actions. Free email alerts at 5 PM.

    Track ZYDUSWELL — Free

    Free account · 2 AI queries/day